Jazz Pharmaceuticals PLC (JAZZ)
110.20
-0.62
(-0.56%)
USD |
NASDAQ |
May 01, 16:00
107.90
-2.30
(-2.09%)
After-Hours: 18:06
Jazz Pharmaceuticals Research and Development Expense (Quarterly): 216.61M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 216.61M |
| September 30, 2023 | 234.40M |
| June 30, 2023 | 209.24M |
| March 31, 2023 | 189.41M |
| December 31, 2022 | 172.56M |
| September 30, 2022 | 148.87M |
| June 30, 2022 | 139.05M |
| March 31, 2022 | 129.98M |
| December 31, 2021 | 155.44M |
| September 30, 2021 | 141.04M |
| June 30, 2021 | 132.70M |
| March 31, 2021 | 76.57M |
| December 31, 2020 | 91.70M |
| September 30, 2020 | 78.65M |
| June 30, 2020 | 78.92M |
| March 31, 2020 | 86.11M |
| December 31, 2019 | 97.38M |
| September 30, 2019 | 79.86M |
| June 30, 2019 | 62.38M |
| March 31, 2019 | 60.10M |
| December 31, 2018 | 56.66M |
| September 30, 2018 | 51.16M |
| June 30, 2018 | 56.13M |
| March 31, 2018 | 62.67M |
| December 31, 2017 | 66.00M |
| Date | Value |
|---|---|
| September 30, 2017 | 47.36M |
| June 30, 2017 | 40.16M |
| March 31, 2017 | 44.93M |
| December 31, 2016 | 44.16M |
| September 30, 2016 | 47.80M |
| June 30, 2016 | 39.09M |
| March 31, 2016 | 31.25M |
| December 31, 2015 | 29.46M |
| September 30, 2015 | 50.78M |
| June 30, 2015 | 27.83M |
| March 31, 2015 | 27.18M |
| December 31, 2014 | 24.56M |
| September 30, 2014 | 22.42M |
| June 30, 2014 | 20.09M |
| March 31, 2014 | 18.11M |
| December 31, 2013 | 13.81M |
| September 30, 2013 | 11.83M |
| June 30, 2013 | 9.25M |
| March 31, 2013 | 6.747M |
| December 31, 2012 | 7.277M |
| September 30, 2012 | 6.92M |
| June 30, 2012 | 2.321M |
| March 31, 2012 | 3.959M |
| December 31, 2011 | 3.764M |
| September 30, 2011 | 3.279M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
62.38M
Minimum
Jun 2019
234.40M
Maximum
Sep 2023
132.68M
Average
132.70M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Alkermes PLC | -20.76M |
| Endo International PLC | 28.14M |
| Medtronic PLC | 695.00M |
| Perrigo Co PLC | 29.60M |
| Iterum Therapeutics PLC | 9.744M |